Wellington Management Group LLP Purchases 7,624 Shares of Emergent Biosolutions Inc. $EBS

Wellington Management Group LLP increased its position in shares of Emergent Biosolutions Inc. (NYSE:EBS) by 5.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 142,966 shares of the biopharmaceutical company’s stock after buying an additional 7,624 shares during the period. Wellington Management Group LLP owned 0.26% of Emergent Biosolutions worth $695,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of EBS. Millennium Management LLC raised its stake in Emergent Biosolutions by 83.0% during the fourth quarter. Millennium Management LLC now owns 1,481,906 shares of the biopharmaceutical company’s stock worth $14,167,000 after buying an additional 671,947 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Emergent Biosolutions by 67.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,104,058 shares of the biopharmaceutical company’s stock worth $10,554,000 after buying an additional 444,790 shares during the last quarter. Prescott Group Capital Management L.L.C. raised its stake in Emergent Biosolutions by 198.9% during the first quarter. Prescott Group Capital Management L.L.C. now owns 627,671 shares of the biopharmaceutical company’s stock worth $3,050,000 after buying an additional 417,671 shares during the last quarter. Palisade Capital Management LP raised its stake in Emergent Biosolutions by 21.6% during the first quarter. Palisade Capital Management LP now owns 1,141,589 shares of the biopharmaceutical company’s stock worth $5,548,000 after buying an additional 202,857 shares during the last quarter. Finally, Man Group plc bought a new position in Emergent Biosolutions during the fourth quarter worth $1,690,000. Institutional investors own 78.40% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $14.33.

Insider Transactions at Emergent Biosolutions

In other news, Director Donald W. Degolyer sold 7,844 shares of Emergent Biosolutions stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $8.65, for a total transaction of $67,850.60. Following the completion of the transaction, the director directly owned 137,659 shares in the company, valued at $1,190,750.35. This trade represents a 5.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kathryn C. Zoon sold 7,086 shares of Emergent Biosolutions stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $8.87, for a total transaction of $62,852.82. Following the transaction, the director owned 71,799 shares of the company’s stock, valued at $636,857.13. This represents a 8.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.20% of the stock is owned by company insiders.

Emergent Biosolutions Trading Down 1.3%

NYSE:EBS opened at $8.29 on Tuesday. The company has a current ratio of 5.66, a quick ratio of 3.00 and a debt-to-equity ratio of 1.25. The stock has a market capitalization of $442.00 million, a price-to-earnings ratio of 3.38 and a beta of 2.03. The firm has a fifty day simple moving average of $7.49 and a two-hundred day simple moving average of $6.43. Emergent Biosolutions Inc. has a 12 month low of $4.02 and a 12 month high of $12.73.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.42. The business had revenue of $140.90 million during the quarter, compared to analysts’ expectations of $148.55 million. Emergent Biosolutions had a net margin of 16.38% and a return on equity of 24.63%. Analysts expect that Emergent Biosolutions Inc. will post -0.63 EPS for the current fiscal year.

About Emergent Biosolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.